Positive outcome of Interim Analysis of pivotal Alpharadin study: Primary endpoint met in Phase III ALSYMPCA study
Press ReleaseConatus Pharmaceuticals Inc. announces interim results from a clinical trial with CTS-1027
Press ReleaseCompletion of Versartis Series B Financing
Press ReleaseAdvent Venture Partners today announced the final close of a $120M (£75M) venture capital fund, to be called Advent Life Sciences
Press ReleaseScrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit. This year, from a strong field, the judges chose Algeta as the winner.
In The NewsAvila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV).
Press Release